Although b-cell dysfunction in cystic fibrosis (CF) leads to diabetes, the mechanism by which the cystic fibrosis transmembrane conductance regulator (CFTR) channel influences islet insulin secretion remains debated. We investigated the CFTR-dependent islet-autonomous mechanisms affecting insulin secretion by using islets isolated from CFTR knockout ferrets. Total insulin content was lower in CF as compared with wild-type (WT) islets. Furthermore, glucose-stimulated insulin secretion (GSIS) was impaired in perifused neonatal CF islets, with reduced first, second, and amplifying phase secretion. Interestingly, CF islets compensated for reduced insulin content under static low-glucose conditions by secreting a larger fraction of islet insulin than WT islets, probably because of elevated SLC2A1 transcripts, increased basal inhibition of adenosine triphosphatesensitive potassium channels (K-ATP), and elevated basal intracellular Ca 2+ . Interleukin (IL)-6 secretion by CF islets was higher relative to WT, and IL-6 treatment of WT ferret islets produced a CF-like phenotype with reduced islet insulin content and elevated percentage insulin secretion in low glucose. CF islets exhibited altered expression of INS, CELA3B, and several b-cell maturation and proliferation genes. Pharmacologic inhibition of CFTR reduced GSIS by WT ferret and human islets but similarly reduced insulin secretion and intracellular Ca 2+ in CFTR knockout ferret islets, indicating that the mechanism of action is not through CFTR. Single-molecule fluorescent in situ hybridization, on isolated ferret and human islets and ferret pancreas, demonstrated that CFTR RNA colocalized within KRT7 + ductal cells but not endocrine cells. These results suggest that CFTR affects b-cell function via a paracrine mechanism involving proinflammatory factors secreted from isletassociated exocrine-derived cell types. (Endocrinology 158: 3325-3338, 2017) 
cretion by CF islets was higher relative to WT, and IL-6 treatment of WT ferret islets produced a CF-like phenotype with reduced islet insulin content and elevated percentage insulin secretion in low glucose. CF islets exhibited altered expression of INS, CELA3B, and several b-cell maturation and proliferation genes. Pharmacologic inhibition of CFTR reduced GSIS by WT ferret and human islets but similarly reduced insulin secretion and intracellular Ca 2+ in CFTR knockout ferret islets, indicating that the mechanism of action is not through CFTR. Single-molecule fluorescent in situ hybridization, on isolated ferret and human islets and ferret pancreas, demonstrated that CFTR RNA colocalized within KRT7 + ductal cells but not endocrine cells. These results suggest that CFTR affects b-cell function via a paracrine mechanism involving proinflammatory factors secreted from isletassociated exocrine-derived cell types. (Endocrinology 158: 3325-3338, 2017) C ystic fibrosis (CF) is caused by mutations in a chloride channel called the CF transmembrane conductance regulator (CFTR). Diabetes is a common comorbidity in CF, occurring in 40% to 50% of adults (1) . CF-related diabetes (CFRD) results primarily from deficient insulin secretion and b-cell dysfunction (2-4), but also involves variable degrees of insulin resistance (5) . Patients with more severe and early exocrine pancreatic disease have a greater chance of developing CFRD later in life (6) . However, patients with CFRD typically retain ;50% of their b-cell mass postmortem (7) , and this degree of b-cell loss is thought to be insufficient alone to cause diabetes (8) .
Three major hypotheses have been proposed for the pathogenesis of impaired insulin secretion in CFRD: (1) b-cell dysfunction results from pancreas-extrinsic CFTR defects (e.g., intestinal pathology leading to altered incretin responses) (9, 10) , (2) b-cell dysfunction results from oxidative stress and inflammatory-based remodeling of islets during and after exocrine pancreas decline (9) (10) (11) , and (3) b-cell dysfunction results from cellintrinsic CFTR-dependent mechanisms of insulin secretion (12) (13) (14) . Although there is evidence to support each of these hypotheses, a clear resolution to the question of whether CFTR functions within the b-cell or other islet cell types to support insulin secretion has yet to be determined.
Endocrine pancreas-related abnormalities have been studied in multiple animal models of CF, including mice, ferrets, and pigs. Two groups have reported CFTR expression in cultured mouse (MIN6) and rat (RINm5F) b-cell lines (12, 13) , and CFTR immunodetection localized predominantly to a-cells in the rat pancreas (15) . Whole-cell patch clamp studies have also demonstrated that CFTR inhibitors (GlyH-101 and CFTRinh-172) block a chloride channel needed for exocytosis of insulin granules in human and mouse b-cells (12) . A supporting study demonstrated that CFTR inhibitors reduce glucose-stimulated whole-cell current, membrane depolarization, Ca 2+ oscillations, and insulin secretion in mouse primary b-cells and DF508-CFTR mutant mouse islets (13) . By contrast, others have suggested that the mild insulin secretion defects in DF508-CFTR mutant mouse islets are caused by decreased insulin content and that, in vivo, CF mice have normal b-cell function as assessed by hyperglycemic clamps (16) . Interestingly, young CF mice (12 to 18 weeks of age) have increased glucose tolerance caused by heightened insulin sensitivity, whereas older mice (24 weeks) have increased insulin resistance with a coincident decline in b-cell mass (16) . These studies underscore the debate as to whether CFTR-dependent b-cell defects exist in CF mouse models.
CF ferrets are born with abnormal glucose tolerance and reduced first phase insulin secretion (17) , despite the lack of overt pancreatic structural damage at birth or evidence of insulin resistance (17, 18) . CF pigs are also born with abnormal glucose tolerance and impaired insulin secretion, despite sparing of islet mass (19) ; however, in this model, exocrine pancreatic damage initiates in utero, and CF pigs are born with reduced pancreatic exocrine mass (20) . Studies in isolated neonatal CF ferret islets support the notion that islet-intrinsic CFTR defects impair glucose-stimulated insulin secretion (GSIS) (17) .
However, impaired GSIS in neonatal CF ferret islets was caused by a heightened baseline percentage of insulin secretion at low glucose as a percentage of total islet insulin (17) .
The CF ferret undergoes rapid inflammatory-mediated remodeling of the exocrine and endocrine pancreas within the first 3 months of life, which leads to agedependent pathologies in glycemic regulation (11) . During the peak of pancreatic inflammation (1 to 2 months old), spontaneous diabetic-level hyperglycemia occurs, with a reduction in b-cell mass. Notably, in the third month of life pancreatic inflammation and hyperglycemia rapidly subside while b-cell mass rises and pancreatic expression of islet hormones, PPARg, and adiponectin increases (11) . Thus, active CF exocrine pancreatic inflammation early in life adversely affects b-cell function but may also lead to functionally productive remodeling of the endocrine pancreas. A similar trend of early life glucose intolerance, followed by normoglycemia, has been found in human children with CF (18) . However, the relative contribution of CFTR defects to cell-intrinsic and cell-extrinsic b-cell dysfunction remains unclear.
We sought to determine how CFTR affects islet insulin secretion in ferrets by using the CFTR knockout (CFTR-KO) model and CFTR inhibitors. Our findings suggest that CFTR expression in exocrine duct cells intimately associated with neonatal cultured islets affects insulin secretion, islet insulin content, and the transcription of genes that influence b-cell function, maturation, and differentiation. Surprisingly, we found that the CFTR inhibitor CFTRinh-172 has effects on both islet Ca 2+ fluxes and insulin secretion in CFTR-KO islets, raising questions about its specificity in interrogating CFTRdependent insulin secretion. We demonstrated that CFTR messenger RNA (mRNA) is limited to ductal cells in islets and pancreas and absent in the major islet endocrine cell types. These findings reflect recent data from single-cell transcriptome analysis of human and mouse islets. In summary, our findings suggest that CFTR expression in exocrine cells affects islet insulin secretion through the secretion of factors such as interleukin (IL)-6.
Material and Methods

Source of islets and tissues
All animal experimentation was approved by the Institutional Animal Care and Use Committee. The previously described CFTR exon-10 disrupted ferret (21, 22) model was used for pancreatic tissue and islet isolation from newborn animals. Adult ferret islets were isolated as previous described (23) . Neonatal CF and wild-type (WT) ferret islet cultures were generated from both male and female animals as previously described (17, 24) . Nondiabetic human islets were obtained from the Integrated Islet Distribution Program.
Measurements of hormone and cytokine secretion from cultured islets
Insulin was measured with a human insulin enzyme-linked immunosorbent assay kit (catalog no. IS130D; Calbiotech, Spring Valley, CA) when measured in plasma and for singleanalyte measurements of islet insulin secretion. For multihormone measurement, insulin, glucagon, and pancreatic polypeptide (PP) were measured with a human Bio-Plex Assay (catalog no. HMHEMAG-34K; Millipore, Billerica, MA). IL-6, IL-8, and tumor necrosis factor (TNF)-a were measured with a Canine Bio-Plex Assay (catalog no. CCYTOMAG-90K; Millipore). The assays were performed as previously described for ferret proteins (11) .
Islet hormone secretion assays
Glucose-responsive hormone secretion assays using isolated islets were performed in static culture as previously described (17) and under perifusion conditions according to an adapted protocol (25) . For static assays, five adult islets (150 to 200 mm diameter) or ;500 cultured neonatal islets were equilibrated for 1 hour in 1.67 mM glucose Krebs-Ringer bicarbonate buffer (KRB) (120 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgCl 2 , 20 mM NaHCO 3 , 5 mM HEPES, pH 7.4) at 37°C (human islets) or 38.5°C (ferret islets). Each group of islets was then divided equally into either 1.67 mM or 16.7 mM glucose/ KRB and cultured for 1 hour. Agonist or inhibitors were added after the initial equilibration period at the following concentrations: diazoxide (DAZ), 100 mM; and CFTRinh-172, 20 mM. Secreted analytes were calculated on a per-islet basis for adult islets or as percentage insulin secretion (secreted insulin in the media/total insulin in the media and islets at the end of the experiment) and absolute total insulin secretion for neonatal islets as previously described (17) . Total islet insulin was evaluated by acetic acid ethanol extraction as previously described (17) . Static insulin secretion assays were also performed on neonatal WT islets that had been treated with 1 ng/mL recombinant human IL-6 (catalog no. 7270-IL-025; R&D Systems, Minneapolis, MN) for 24 hours before the experiment was performed in the sustained presence of IL-6.
For islet perifusion assays, ferret islets in a closed smallvolume chamber were equilibrated by perfusion with 1.67 mM glucose/KRB at 38.5°C for 30 minutes. The medium used for both static and perifusion assays was identical. First-and second-phase insulin secretion was assessed after a step change to 16.7 mM glucose. The amplifying phase of insulin secretion was assessed as previously described (25, 26) by incubating islets in 16.7 mM glucose/KRB, DAZ (100 mM), and forskolin (1 mM) followed by the addition of tolbutamide (100 mM). Islet insulin content was quantified at the end of each experiment and the percentage insulin secretion per minute calculated.
Fura-2 calcium imaging in islets
Islets were loaded with 2 mg/mL Fura-2 for 40 minutes in 1.67 mM glucose/KRB and then rinsed three times with 1.67 mM glucose/KRB and incubated 20 to 30 minutes before baseline measurements. For media changes, 10 chamber volumes (20 mL) of 16.7 mM glucose/KRB, followed by KRB (40 mM KCL replacing 40 mM NaCl) at the end of the experiment, were perfused through the chamber. MetaFluor software captured pairs of fluorescent images every 3 seconds with a 510-nM emission filter and alternating 340/380 excitation filters and calculated the average fluorescence intensity ratio.
RNA quantification
Islet RNA expression was measured with a QuantiGene Plex Assay Kit (Thermo Fisher Scientific). Bead-based oligonucleotide probe sets specific for 41 ferret RNAs were developed by Thermo Fisher Scientific (Supplemental Data File 1). Islet homogenates were prepared with the QuantiGene Sample Processing Kit and quantified as previously described (11), with peptidylprolyl isomerase B (PPIB) used as the housekeeping gene for normalization of each gene/sample.
RNA in situ hybridization for CFTR, KRT7, and islet hormones on pancreas
In situ colocalization of CFTR RNA and cellular marker gene RNAs (INS, GCG, PPY, SST, and KRT7) was performed with QuantiGene ViewRNA kits (Thermo Fisher Scientific, Waltham, MA) as previously described (11) . Pancreata were fixed in 10% neutral buffered formalin, processed and embedded in paraffin, and sectioned at 10 mm. Sections were baked for 1 hour at 60°C. After baking, slides were rinsed in xylene two times for 10 minutes per rinse, incubated in 100% EtOH two times for 10 minutes per rinse, and then air dried. Slides were then processed with the QuantiGene ViewRNA (catalog no. QVT0012; Thermo Fisher Scientific) kit. Slides were incubated in 13 pretreatment (catalog no. QVT0500; ThermoFisher Scientific) buffer at 95°C for 10 minutes, followed by 15 minutes protease digestion at 40°C and postfixation with 10% neutral buffered formalin for 5 minutes. The type 1 and type 6 RNA targeting probes were diluted into probe set diluent (catalog no. QVT0511; Thermo Fisher Scientific) and then simultaneously incubated on tissue sections for 3 hours at 40°C in a humidified chamber. After hybridization, slides were washed at room temperature with Thermo Fisher Scientific proprietary washing buffer. Slides were then incubated with preamplifier oligonucleotide and amplifier oligonucleotide at 40°C for 20 minutes in a humidified chamber. To develop the chromogenic signal for each probe, alkaline phosphataseconjugated type 1 detection probe was hybridized to slides at 40°C for 20 minutes, followed by reaction with Fast-Red substrate (catalog no. QVT0506; Thermo Fisher Scientific) in naphthol buffer. The reaction was then terminated with Stop QT buffer (catalog no. QVT0517; Thermo Fisher Scientific) to deactivate remaining alkaline phosphatase, and the process was repeated with alkaline phosphatase-conjugated type 6 detection probe and Fast-Blue substrate (catalog no. QVT0505; Thermo Fisher Scientific) in 0.1 M Tris maleate buffer. Lastly, slides were rinsed in phosphate-buffered saline (PBS) three times for 5 minutes each and then immersed in Vectashield Mounting Medium with 4 0 ,6-diamidino-2-phenylindole (DAPI; catalog no. H-1500; Vector Laboratories, Burlingame, CA) before coverslipping and imaging on a Zeiss 700 confocal microscope. Both type 1 and type 6 RNA targeting probes were designed by Thermo Fisher Scientific (Supplemental Data File 2). Ferret accessions XM_004759670 (CFTR), XM_004743954 (GCG), XM_004772581 (PPY), XM_004745230 (SST), and XM_004774693 (KRT7) were submitted to Thermo Fisher Scientific for design and synthesis of RNA targeting probes. In this case, the type 1 RNA targeting probe was designed to detect ferret CFTR mRNA (catalog no. VF1-16852), and type 6 RNA targeting probes were designed to detect ferret INS (catalog no. VF6-16854), GCG (catalog no. VF6-16853), PPY (catalog no. VF6-16855), SST (catalog no. VF6-17246), and KRT7 (catalog no. VF6-17245) mRNA.
RNA in situ hybridization for CFTR, KRT7, and islet hormones on dissociated islet cells Dissociated adult human or ferret islet cells were fixed with freshly prepared 4% formaldehyde in PBS for 1 hour at room temperature. After washing with PBS, ;20,000 total cells in a 20 mL volume were placed onto poly-L-lysine coated microscope glass coverslips and baked in an oven at 50°C for 40 minutes. Coverslips were then submerged in 100% ethanol at 220°C for storage until use. Before analysis, baked cells were rehydrated in 70% ethanol, followed by 50% ethanol, and then washed with PBS. Single-molecule fluorescent in situ hybridization (smFISH) was performed with a QuantiGene ViewRNA ISH Cell Assay kit (Thermo Fisher Scientific). Rehydrated cells were permeabilized with Working Detergent Solution (Thermo Fisher Scientific) for 5 minutes at room temperature and then digested with Protease (1:4000; Thermo Fisher Scientific) in PBS for 10 minutes at room temperature. The cells were then hybridized for 3 hours at 40°C with custom-designed QuantiGene ViewRNA probes (1:100 dilution) against ferret or human transcripts (CFTR, INS, GCG, SST, PPY, or KRT7). The ferret type 1 RNA target probes were developed by Thermo Fisher Scientific (Supplemental Data File 2). For human samples, the targeting probes were already available for purchase from Thermo Fisher Scientific for type 1 RNA targeting probes that detect human CFTR mRNA (catalog no. VA1-12343) and the type 6 RNA targeting probes that detect human INS (catalog no. VA6-13248), GCG (catalog no. VA6-11294), PPY (catalog no. VA6-11294), SST (catalog no. VA6-17244), and KRT7 (catalog no. VA6-11562) mRNA. Unbound probes were removed with Wash Buffer (Thermo Fisher Scientific), and then the bound probes were amplified with PreAmp hybridization buffer (1: 25 dilution; Thermo Fisher Scientific) for 30 minutes at 40°C, followed by incubation with Amp hybridization bugger (1: 25 dilution; Thermo Fisher Scientific) for 30 minutes at 40°C. A labeled probe mixture (1:25 dilution; Thermo Fisher Scientific) targeting the individual probe types was added for 30 minutes at 40°C. The cells were then mounted with Prolong Gold antifadent reagent containing DAPI (Life Technologies, Carlsbad, CA) and imaged with a Zeiss 700 confocal microscope.
Control experiments evaluating the human and ferret CFTR probes were performed before smFISH on pancreas and islets. A genetic approach was used in which baby hamster kidney (BHK) cells (which lack CFTR) were generated to express either human or ferret CFTR. Plasmid expression constructs encoding either the human or ferret CFTR complementary DNA were transfected into BHK cells, and polyclonal populations were selected. smFISH was then performed against the CFTR expressing and parental (untransfected) population of cells via the methods described earlier.
Whole mount staining of newborn ferret pancreas
Newborn ferret pancreata were fixed in 4% paraformaldehyde in PBS overnight at 4°C. Pancreatic tissues were diced manually (average size 0.5 3 0.5 mm) and equilibrated in absolute methanol (MeOH) for 1 hour on ice and then in MeOH/DMSO/H 2 O 2 (4:1:1) for 2 hours at room temperature. Tissue was stored in absolute MeOH until use. For immunostaining, the following steps were performed. First, the tissue was rehydrated with PBS. Second, the tissue was blocked in PBS containing 10% goat serum and 0.05% Triton X-100 for 2 hours at room temperature. Third, the tissue was incubated with primary antibodies in the PBS containing goat serum and Triton X-100 overnight at 4°C. Finally, after washing with PBS, the secondary antibodies were incubated overnight at 4°C. The primary antibodies used were anti-asmooth muscle actin [a-SMA; mouse monoclonal antibody, Research Resource Identifier (RRID): AB_476701, catalog no. A2547; Sigma-Aldrich, St. Louis, MO], anti-desmin (rabbit polyclonal antibody, RRID: AB_476701, catalog no. D8281; Sigma-Aldrich, St. Louis, MO) and Cytokeratin 7 Antibody (mouse monoclonal antibody, RRID: AB_921846, catalog no. NB120-9021; Novus Biologicals, Littleton, CO).
Results
GSIS is impaired in CF ferret islets
To interrogate the islet-autonomous impact of CFTR on insulin secretion, we performed a perifusion-based assay to assess various phases of insulin secretion in response to glucose challenge in neonatal ferret islets. CF islets demonstrated reduced percentage insulin secretion at baseline and during first and second phases of insulin secretion after glucose challenge, as compared with WT ferret islets (Fig. 1A-1C) . Similarly, glucose and cyclic adenosine monophosphate (cAMP) amplified insulin secretion stimulated by tolbutamide was also significantly reduced in perifused CF ferret islets ( Fig. 1D and  1E) . Similar results and statistics were obtained when the data in Fig. 1A-1E were plotted as absolute total secreted insulin (data not shown). These findings demonstrate that neonatal CF ferret islets have impaired glucose-responsive insulin secretion in comparison with WT islets.
We have previously shown that isolated neonatal islets from CFTR-KO ferrets also lack GSIS in static culture, although interestingly this result was caused by a heightened baseline percentage insulin secretion at low glucose (17) . To better understand why CFTR-KO islets have a heightened percentage insulin secretion in low glucose and inability to increase that level of secretion in response to high glucose, we asked whether insulin secretion under low-glucose static conditions remained under the control of adenosine triphosphate-sensitive potassium (K-ATP) channels. As previously, we found that CF, compared with WT, neonatal ferret islets exhibit increased percentage insulin secretion under low glucose conditions (Fig. 1F) . Sustained activation of the K-ATP channel in neonatal CF ferret islets with DAZ reduced the percentage of insulin secretion to baseline levels observed in WT ferret islets treated with DAZ (Fig, 1F) , demonstrating that CF ferret islets secrete a greater proportion of total islet insulin under low glucose because of increased inhibition of K-ATP and not because of uncoupling of this pathway from insulin secretion. However, total insulin secreted during the low-glucose static assays did not differ between genotypes (Fig. 1G) , despite the fact that CF islets had significantly less total islet insulin compared with WT islets (Fig. 1H) . These findings demonstrate that in static cultures CF islets maintain normal levels of insulin secretion in low glucose, but at the expense of secreting a larger fraction of their reduced islet insulin content. Interestingly, DAZ treatment of WT islets led to a significant reduction in total islet insulin, and this effect was not observed in CF islets (Fig. 1H) , suggesting that the activated status of K-ATP differentially influences insulin synthesis in CF and WT neonatal islets.
We reasoned that the altered insulin secretion by CF ferret islets (i.e., impaired insulin secretion in response to high glucose and increased percentage insulin secretion at low glucose due to heightened K-ATP inhibition) may be caused by emerging inflammation in the CF ferret pancreas from which islets were isolated (17, 21) . Because b-cells and islets are exposed to paracrine diffusible factors in vivo, we reasoned that newborn CF ferrets would exhibit excessive insulin secretion at low blood glucoses and lower levels of insulin secretion at higher blood glucose. Indeed, when we evaluated plasma insulin and blood glucose levels in nursing newborn CF ferrets, there was a significant negative correlation (P , 0.013) between insulin and glucose (Supplemental Fig. 1A) , with significantly elevated insulin/ glucose ratios and excessive insulin levels occurring inappropriately at low blood glucoses (#45 mg/dL) in comparison with WT animals (Supplemental Fig. 1B and 1C) . By contrast, the expected positive correlation between blood insulin and glucose levels (P , 0.027) was observed in WT newborn ferrets (Supplemental Fig. 1A ). These findings support the notion that in vivo glucose-responsive insulin secretion is dysregulated in newborn CF ferrets.
Intracellular Ca
2+ fluxes are altered in newborn CF ferret islets and inhibited by CFTRinh-172
The finding that neonatal CF ferret islets secrete a greater proportion of islet insulin at low glucose because of enhanced K-ATP inhibition suggested that intracellular Ca 2+ fluxes would be elevated at baseline. Indeed, intracellular Ca 2+ was significantly elevated in isolated CF ferret islets at low glucose as compared with WT controls ( Fig. 2A and 2B ). Furthermore, the glucose-responsive change in intracellular Ca 2+ was significantly lower in CF islets (Fig. 2C) . These findings are consistent with CF islets maintaining an elevated level of K-ATP inhibition and increased percentage insulin secretion under low-glucose static conditions (Fig. 1F) . Furthermore, the reduced glucoseresponsive change in intracellular Ca 2+ observed in CF ferret islets is also consistent with the observed impaired glucose-responsive insulin secretion under perifusion conditions (Fig. 1A-1C ). Several studies have used CFTR inhibitors as a method of demonstrating CFTR involvement in islet and b-cell insulin secretion (12, 13) . To this end, we performed similar experiments to evaluate how CFTRinh-172 alters intracellular Ca 2+ flux and insulin, glucagon, and PP secretion in isolated ferret and human islets. As in previous reports, CFTRinh-172 significantly inhibited both the percentage and total insulin secretion by WT ferret neonatal islets in high glucose; however, the same level of inhibition was observed in CFTR-KO islets (Fig. 2D) . Of note, although the percentage insulin secretion by CF islets in high glucose with and without CFTRinh-172 was not different from that of WT controls, the total secreted insulin by CF islets was significantly lower than that of WT islets under both conditions (Fig. 2D) . These findings reflect that the fact that total insulin content of CF islets is significantly lower than that of WT islets and unaffected by CFTRinh-172 ( Fig. 1H and Fig. 2D ). Importantly, CFTRinh-172 significantly reduced glucose-responsive Ca 2+ uptake in neonatal CF ferret islets (Fig. 2E ). These findings suggest that CFTRinh-172 alters b-cell insulin secretion through a CFTR-independent process that influences regulation of intracellular Ca 2+ . In adult WT ferret (Fig. 2F) and human (Fig. 2G) islets, CFTRinh-172 significantly inhibited insulin but not glucagon or PP secretion under high-glucose conditions.
CF ferret islets produce excessive IL-6, which alters insulin secretion and islet insulin content The methods used in this study to generate neonatal ferret islets are based on a procedure designed to isolate functional neonatal pig islets (24) . The Figure 2 . Fura-2-acetoxymethyl ester-Ca 2+ imaging and hormone secretion from ferret and human islets in response to CFTR-KO or CFTRinh-172. (A-C) Neonatal CF and WT ferret islets were loaded with Fura-2 and then equilibrated in 1.67 mM glucose (G1.67) followed by a sequential challenge with 16.7 mM glucose (G16.7) and 40 mM KCl. (A) Absolute 340/380-nm Fura-2 ratio from WT and CF ferret neonatal islets. (B) Absolute 340/380-nm Fura-2 ratios at baseline (Base), peak, and 5 minutes after sequential glucose and high K + stimulation. (C) Data from (A) were used to calculate the percentage increase over baseline for the 340/380-nm ratios at peak and 5 minutes after glucose addition. (D) CFTRinh-172 (20 mM) reduces insulin secretion from CF and WT neonatal ferret islets in the presence of 16.7 mM glucose. Panels show from left to right, percentage insulin secretion, total secreted insulin, and total islet insulin. (E) CFTRinh-172 reduces peak and 5-minute intracellular Ca 2+ after glucose challenge of CF neonatal ferret islets. Data from (B) were normalized to baseline (R min = 0) and high K + (R max = 1) 340/380-nm ratios for each islet's response to glucose for WT and CF islets in the absence of CFTRinh-172. Similar studies were performed with CF islets treated with 20 mM CFTRinh-172 and the high K + normalized 340/380-nm ratios calculated. Shown are the changes in the high K + normalized 340/380-nm Fura-2 ratios at peak and 5 minutes after glucose challenge for each group of islets. (F, G) CFTRinh-172 (20 mM) reduces insulin secretion by (F) adult ferret and (G) human islets in the presence of 16.7 mM glucose but did not alter glucagon or PP secretion. (B, C, and E) Data for all graphs show the mean 6 standard error of the mean for the indicated number (N) of islets with the given number of independent islet preparations or (D, F, G) N of independent experiments. Each neonatal islet experiment generated islets from three or four newborn ferrets of each genotype, whereas each adult islet experiment used one donor. Statistical analysis was performed by two-tailed Student t test, with significance of *P , 0.05, **P , 0.01, and ***P , 0.001. Comparison in (E) is between CF and CF + CFTRinh-172. DMSO, dimethyl sulfoxide.
procedure involves maturation of islets in culture over the course of 9 days, during which b-cell and a-cell content increases to produce functional islets capable of normalizing blood glucose in diabetic mice (24) . During maturation, amylase-producing acinar cells are lost by 3 days in culture, and islets contain ;3% exocrine cells by 9 days in culture. Thus, neonatal islets represent an evolving islet-like niche that probably involves maturation of b-cell and a-cell progenitors. We hypothesized that the emerging proinflammatory state of the newborn CF ferret pancreas might impart altered islet function through exocrine-associated cell types that persist in the maturing islet. To investigate the proinflammatory state of the newborn CF ferret pancreas, we asked whether there was increased activation of pancreatic stellate cells (PaSCs). Desmin-positive PaSCs are major mediators of inflammation in the pancreas and express a-SMA in the activated state (27) . In support of this hypothesis, desminpositive PaSCs of the newborn CF pancreas had an a-SMA-positive activated phenotype, whereas those of the WT pancreas did not (Fig. 3A-3D ). Furthermore, supporting the presence of exocrine cells in porcine neonatal islets (24) , cytokeratin 7 (CK7)-positive ductal cells of cultured ferret neonatal islets associated with the periphery of both CF and non-CF islets ( Fig. 3E and 3F ). Because ductal cells are known to express the highest levels of CFTR among pancreatic cell types (28), we hypothesized that secretions from this cell type could affect endocrine functions of neonatal islets.
To evaluate whether neonatal CF islets retained a proinflammatory state in culture, we assessed the levels of IL-6, TNF-a, and IL-8 in the media of 9-day cultured CF and WT ferret islets. Results from this analysis demonstrated significantly greater (P , 0.01) levels of IL-6 secreted by CF islets, whereas TNF-a was absent and IL-8 levels were not significantly different between genotypes (Fig. 3G) . Importantly, treatment of WT islets with IL-6 significantly increased percentage insulin secretion in low glucose and reduced insulin content (Fig. 3H) , giving rise to a similar phenotype observed in CF ferret islets (Fig. 1F and 1H ). IL-6 treatment of WT ferret islets did not alter total insulin secretion in low glucose (Fig. 3H) , which was a similar finding when we compared CF and WT ferret islets in low glucose (Fig. 1G) .
CFTR influences islet expression of genes associated with both endocrine and exocrine cell types
Given that the maturation of neonatal islets involves dynamic changes in endocrine and exocrine cell components (24), we hypothesized that the increased proinflammatory state of CF neonatal islets could affect both the maturation and function of b-cells. To investigate this possibility, we evaluated 9-day cultured neonatal islets from CF and WT ferrets for transcripts involved in b-cell function and maturation. RNA analysis demonstrated significantly lower INS and GCG transcripts in CF as compared with WT ferret islets but unchanged levels of SST and PPY (Fig. 4A) . This finding is consistent with reduced insulin content in CF mouse islet (16) and CF ferret islets (Fig. 1H  and Fig. 2D ). Transcript levels of most glucose-sensing genes evaluated were mostly unchanged (GLP1R, GCK, SLC2A2, GJD2, KCNJ11, ABCC8); however, SLC2A1 transcripts were significantly elevated in CF ferret islets (Fig. 4B) . Consistent with increased stellate cell activation in the CF pancreas and ductal-derived cells in isolated islets (Fig. 3A-3F ), the expression of the exocrine duct marker gene KRT7 and markers of stellate cell activation and inflammation (ACTA1, ACTA2, and TGFB1) were increased in CF ferret islets (Fig. 4C, 4D ). Interestingly, CELA3B (pancreatic elastase) transcripts were significantly reduced in CF ferret islets (Fig. 4D) . Unexpectedly, there was no significant change in the five cytokines/chemokines evaluated, although CXCL10 and IL6 levels trended higher in CF islets (Fig. 4E) . Several RNAs involved in the transcriptional regulation of b-cell maturation and proliferation (NEUROD1, NEUROG3, PAX4, REG3A, and SER-PINHB1) were increased in CF islets, whereas others such as PDX1 and MAFB remained unchanged ( Fig. 4F and 4G) . Overall, these findings suggest that many genes known to affect both exocrine and endocrine function are altered when islets lack CFTR.
CFTR RNA is expressed in exocrine but not endocrine cell types of islets and pancreas
The most pertinent question regarding CFTR-mediated mechanisms that influence islet insulin secretion is the cell types that express CFTR. Work by others has suggested that CFTR is highly expressed at the protein level in mouse and rat b-cell lines (12, 13) . We sought to use an approach that would avoid antibody specificity problems and chose smFISH to address this question. As a control for specificity, we performed CFTR and INS dual smFISH (two probes simultaneously) on WT and CFTR-KO neonatal ferret pancreas (Fig. 5A-5D ). Whereas INS was detected in both genotypes, CFTR was detected only in the WT pancreas. In WT pancreas, CFTR RNA was not coexpressed in INS (b-cell) (Fig. 5A, 5C , and 5E), GCG (a-cell) (Fig. 5F) , PPY (PP cell) (Fig. 5G) , or SST (d-cell) (Fig. 5H) expressing cells but was expressed in KRT7-expressing ductal cells (Fig. 5I) . Similar findings were observed when smFISH was performed for these markers on dissociated cells from isolated adult ferret and human islets (Fig. 6) . Controls for specificity of smFISH on isolated cells were performed on BHK cells (which do not express endogenous CFTR) engineered to express hCFTR or fCFTR. In these studies, CFTR signal was detected only in the hCFTR and fCFTR expressing cells (Supplemental Fig. 2 ). These findings demonstrate that exocrine-derived duct cells associated with isolated islets express the highest levels of CFTR and support a mechanism by which CFTRdependent duct/islet crosstalk might influence b-cell insulin secretion.
Discussion
Patients with CF who develop CFRD have lower lung function and higher mortality than those without diabetes (29) . A concrete understanding of CFRD pathogenesis is critical to developing effective treatments.
Hypotheses that seek to explain why b-cell function is altered in CF can be divided into two broad categories: The b-cell intrinsic hypothesis proposes that CFTR functions cell-autonomously to control insulin secretion; the b-cell extrinsic hypothesis proposes that CFTR functions in non-cell-autonomous fashion to alter insulin secretion. This latter hypothesis could involve a number of cell types (non-b-cells), resident in the exocrine pancreas, endocrine pancreas, or other organs (i.e., the gut), that functionally affect insulin secretion through paracrine or endocrine signaling. Although these hypotheses are not mutually exclusive, determining which mechanism plays a dominant role is critical to piecing together a firm understanding of CFRD pathogenesis. (H) Eight-day WT neonatal ferret islets were divided into two equal groups, treated with 1 ng/mL IL-6 or vehicle for 24 hours, and then used for insulin secretion assays in low glucose (1.67 mM) under 1 hour static conditions in the continued presence of 1 ng/ mL IL-6 or vehicle. Panels show from left to right, percentage insulin secretion, total secreted insulin, and total islet insulin. Data for all graphs show the mean 6 standard error of the mean for the number (N) of experiments in each panel. Each experimental set of islets was derived from three or four independent animals. Statistical analysis was performed by paired two-tailed Student t test, with significance of **P , 0.01.
Growing evidence supports the notion that CFTR plays an islet-intrinsic role in regulating insulin secretion (14) ; however, the mechanism and CFTR-expressing islet-associated cell types that control insulin secretion remain unclear. Studies in immortal rodent b-cell lines support the hypothesis for a cell-autonomous role of CFTR in regulating insulin secretion (12, 13, 30) . In primary isolated islets from DF508-CFTR mice, there is disagreement as to whether altered insulin secretion is caused by altered CFTR-mediated chloride conductance by the b-cell (13) or reduced insulin content of islets (16) . Given that CF mice do not spontaneously develop diabetes, we sought to evaluate whether these mechanisms apply to the CF ferret model, which spontaneously develops CFRD (11, 17) .
Overall, our findings demonstrate that neonatal CF ferret islets have impaired glucose-responsive insulin secretion. However, subtle differences between static and perifusion assays for insulin secretion should be noted. Under static low-glucose conditions, CF ferret islets secrete a larger proportion of total islet insulin (percentage insulin) (Fig. 1F ) but contain ;30%-50% less insulin than WT ferret islets (Fig. 1H and Fig. 2D ). This feature of the CF islet is consistent with increased basal K-ATP inhibition (Fig. 1F ) that raises basal intracellular Ca 2+ ( Fig. 2A and 2B ) and increased glucose uptake due to elevated expression of SLC2A1 (Glut1) (Fig. 4B) . Increased IL-6 production by CF ferret islets appears to be partially responsible for the reduced islet insulin content and increased percentage insulin secretion, as compared with WT islets, given that IL-6 treatment of WT islets reproduces this effect ( Fig. 3G and 3H) . Under perifusion conditions, neonatal CF ferret islets demonstrated reduced first-and second-phase insulin secretion in response to glucose, as well as a reduced glucose and cAMP amplified insulin secretion triggered by tolbutamide (Fig. 1A-1E ), consistent with a significant reduction in glucose-stimulated Ca 2+ uptake (Fig. 2C ) in comparison with WT islets. Because CF islets are isolated from a pancreas with enhanced PaSC activation (Fig. 3A-3D) , it is plausible that this proinflammatory state persists in culture and affects the level of IL-6 secretion and probably other cytokines responsible for the functional changes in CF islets. CFTR inhibitors have been previously used to study CFTR-dependent electrical endpoints in b-cells and insulin secretion by b-cell lines and islets (12, 13) . Although we similarly found that CFTRinh-172 can reduce GSIS in neonatal and adult WT ferret islets and human islets (Fig. 2D, 2F , and 2G), the specificity of inhibition is questionable because this inhibitor also impaired GSIS and glucose-responsive Ca 2+ uptake by CFTR-KO islets ( Fig. 2D and 2E ). Thus, CFTRinh-172 affects CFTR-independent processes that control insulin secretion.
Severe inflammation in the CF ferret pancreas at 1 to 2 months of age is associated with hyperglycemia and impaired b-cell function and mass (11) . This inflammatory process appears to drive an adipogenic transition at ;3 months of age, which leads to improved glycemic regulation. This transition is marked by a rise in PDX1 and islet hormone expression, as well as increased b-cell mass, suggesting that inflammatory factors may positively affect islet regeneration after glycemic crisis in CF ferret (11) . Thus, the observed increases in expression of b-cell proliferation and maturation genes of neonatal CF ferret islets (Fig. 4F and  4G ) may be secondary to their increased proinflammatory status. For example, REG3A expression is transcriptionally activated by IL-6 (31), and both are elevated in CF ferret islets cultures (Fig. 3G and Fig. 4F ). Other secreted candidate molecules that might increase expression of b-cell proliferative markers in CF islets include Serpinb1 (Fig. 4F) , which is thought to increase b-cell proliferation by inhibiting neutrophil and pancreatic (CELA3B) elastase (32) . Interestingly, CELA3B expression decreased, while SERPINB1 increased, in CF islets ( Fig. 4D and 4F ). Cela3b is a marker of pancreatic acinar cells but is also expressed in islets and at low levels in b-cell (33) and elevated in isolated islets from a Zucker rat model of type 2 diabetes (T2D) (34) . The functional significance of CF islet-associated changes in CELA3B and SERPINB1 expression remains unclear but could involve abnormal CFTR-mediated secretion of CELA3B from exocrinederived cells and feedback-regulated changes in expression of CELA3B and its inhibitor SERPINB1.
A clear understanding CFTR-dependent mechanisms of islet insulin secretion must be based on knowledge of the islet-associated cells that express CFTR. Using smFISH, we found CFTR RNA expression only in KRT7 + (CK7) exocrine-derived cells of ferret pancreas and dissociated cells from ferret and human islets, and no evidence for CFTR expression in INS (b-cell), GCG (a-cells), PPY (PP cells), or SST (d-cells) expressing endocrine cells (Figs. 5 and 6 ). These findings of CFTR gene expression in exocrine but not endocrine cell types of the ferret and human islet are similar to those observed by single-cell RNA sequencing (scRNA-seq) of dissociated islet cells from human (35, 36) and mouse (35) (Supplemental Fig. 3 ). Using data from these previous reports, we graphed the levels of CFTR expression for the various cell types identified. Of 1886 sequenced cells from two strains of cultured mouse islets (35), 14.6% were classified as ductal cells (Supplemental Fig. 3A) . Of the 275 mouse ductal cells sequenced, 27.8% expressed CFTR .4 TPM, with an upper level of expression at 692 TPM per cell. Of the 12 additional cell types identified in mouse islets, CFTR expression was not detected with the exception of one b-cell (0.11%) and one d-cell (0.45%) at ;8 to 10 TPM per cell. Given that the method used in this study was Drop-Seq, these infrequent data points could be duplet captured cells. Similar data were generated from this same laboratory using cultured normal human islets and Drop-Seq (35) (Supplemental Fig. 3B ). Of 8569 sequenced cells, 1077 ductal cells were identified, composing 12.6% of total islet cells sequenced, and 50.3% (524/1077) of ductal cells expressed CFTR .4 TPM per cell with an upper level of expression at ;12,589 TPM per cell (Supplemental Fig. 3B) . Although low-level CFTR expression averaging 9 and 10 TPM per cell was observed in 11 (0.4%) b-cells and 12 (0.5%) a-cells, respectively, it is difficult to determine whether this infrequent cell phenotype is the result of duplet cell capture. Results from a second study sequenced 1097 cells from cultured normal human islets and 1112 cells from cultured T2D human islets by using fluorescence-activated cell sorting isolation of single cells before scRNA-seq (36) (Supplemental Fig. 3C ). In the combined data set from this study, 17.4% and 8.3% of cells sequenced were identified as ductal and acinar cells, respectively (Supplemental 0% of each population, respectively, contained 2 to 6 RPKM per cell of CFTR, and none were greater than this level. In summary, scRNA-seq results from mouse and human islets demonstrate the presence of ductal cells that express the majority of CFTR in the islet. Although it is difficult to conclude whether low-level expression of CFTR (2 to 6 TPM or RPKM per cell) in a minority of b-cells is biologically meaningful, these scRNA-seq results support our smFISH data demonstrating that most endocrine cells of the islet express no CFTR.
We propose a model where CFTR-expressing exocrine-derived cells affect b-cell function. Several findings support this hypothesis. First, smFISH and previously published scRNA-seq studies on isolated human, mouse, and ferret islet cells demonstrate the existence of ductal cell populations that express the majority of CFTR in the islet. In both neonatal CF and WT ferret islets, CFTR + KRT7 + ductal cells form a rim around neonatal islets (Fig. 3E, 3F ). This organized feature of islet ductal cells may be unique to neonatal islets, and thus this neonatal islet model may be well suited to evaluate exocrine/endocrine axis function. Second, neonatal CF ferret islets secrete higher levels of IL-6 (Fig. 3G) , and this factor alone can reduce insulin content in neonatal WT ferret islets and increase percentage insulin secretion at low glucose (Fig. 3H) , both of which are features of neonatal CF ferret islets (Fig. 1F, 1H ). Third, neonatal CF ferret islets are derived from a pancreas with excessive stellate cell activation (Fig. 3A-3D ), which could account for the RNA signatures of stellate cell activation (ACTA1,2/a-SMA) and elevated proinflammatory factors (TGFB1, CXCL10, and IL-6) in CF ferret islets ( Fig. 4C-4E ). Fourth, insulin protein content and INS expression were reduced in CFTR-KO ferret islets (Figs. 1H, 2D , and 4A), whereas five b-cell maturation and differentiation transcripts were upregulated ( Fig. 4F  and 4G ). Numerous studies have implicated ductal precursors as progenitors of the b-cell during development or after injury (37) (38) (39) (40) . One possible explanation of the current findings is that neonatal islets represent a developmental state similar to in utero pancreatic development of the exocrine and endocrine compartments. In this context, CFTR-expressing ductal cells may serve as a progenitor pool for formation of islet endocrine cell types. Disruption of CFTR function may alter properties of this niche through CFTR-dependent secretory products such as IL-6. This in turn could disrupt duct-to-b-cell differentiation pathways that lead to an immature b-cell with less insulin content and altered glucose-responsive insulin secretion. The finding of infrequent human b-cells with very low abundance of CFTR transcripts by scRNAseq (2 to 6 TPM per cell) may reflect a developmental transition of a CFTR-expressing ductal cell to a maturing b-cell in the process of extinguishing CFTR expression. Our findings offer insights into the CFTR-dependent abnormalities that are intrinsic to the CF islet and affect insulin secretion. Our data suggests that islet-associated exocrine cells express the majority of, if not all, CFTR within islets and probably influence b-cell function through exocrine-derived factors such as IL-6 that alter properties of the islet, including insulin content. Furthermore, we found that pharmacologic inhibition of CFTR alters CFTRindependent pathways that influence insulin secretion and intracellular Ca 2+ and thus should be used with caution when interrogating and interpreting islet function. Additional research is needed to determine how CFTR-dependent exocrine-derived factors alter b-cell function and whether a direct lineage relationship between ductal progenitors and b-cells of islets involves CFTRdependent functions. Such pathways may be highly relevant to exocrine pancreatic disease and islet remodeling in CF.
